Vivani Medical, Inc. (VANI) SEC Filings

Vivani Medical, Inc. furnished an investor slide presentation used at the Emerging Growth Conference in New York on July 15, 2026 at 4:10 p.m. Eastern Time. The presentation, delivered by CEO Dr. Adam Mendelsohn, includes an update that the company’s first dosing of SLIM-1 is expected in August 2026.

The information in the presentation is provided under Regulation FD, is not deemed filed or subject to liability under Section 18 of the Exchange Act, and is not incorporated by reference into other securities law filings unless expressly referenced.

Vivani Medical, Inc. reports that its wholly owned subsidiary Cortigent, Inc. has signed an Agreement and Plan of Merger with ClearOne, Inc., under which Cortigent will merge into a ClearOne subsidiary and become a wholly owned ClearOne unit. Vivani’s Cortigent equity will be converted at closing into 12,500,000 shares of ClearOne common stock, while ClearOne must complete a concurrent Form S-1 financing of $10,000,000 to $15,000,000 through 2,500,000 to 5,000,000 units, each with one share and a warrant exercisable at $10.00. The merger is subject to stockholder approvals, Nasdaq listing conditions, completion of the financing and other customary closing conditions, and includes a breakup-fee mechanism capped at $250,000. Vivani also announces a separate non-exclusive agreement with Novo Nordisk, allowing Novo Nordisk to internally evaluate Vivani’s NPM-139 semaglutide NanoPortal implant for chronic weight management, alongside plans to start a Phase 1 first-in-human study with Wegovy injections as an active comparator in mid-2026.

Vivani Medical held its 2026 annual stockholder meeting and approved an amended 2022 Omnibus Incentive Plan that increases the common shares reserved for equity awards by 11,000,000, from 10,033,333 to 21,033,333 shares. Stockholders also re-elected six directors, approved executive compensation on a non-binding advisory basis, and ratified BPM LLP as auditor for the year ending December 31, 2026. The meeting reached a quorum with 62,071,530 of 86,235,104 common shares represented in person or by proxy.

Separately, Vivani received approval from Bellberry, a human research ethics committee in Australia, to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant for obesity and chronic weight management. SLIM-1 is designed as an open-label, randomized, active comparator-controlled trial evaluating low-dose NPM-139 versus Wegovy 0.25 mg/week over four weeks in obese or overweight subjects, with 10 participants per group, focusing on safety, tolerability, and pharmacokinetics while also measuring weight loss.

Vivani Medical director August J. Moretti received a grant of non-qualified stock options covering 36,000 shares of common stock at an exercise price of $1.22 per share. The award was made under Vivani’s Non-Employee Director Compensation Policy and vests in monthly installments over three years, with the options expiring on June 23, 2036. This is a compensation-related equity grant rather than an open-market purchase or sale.

Vivani Medical, Inc. filed an initial Form 3 for director August J. Moretti. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, and no derivative positions listed in the derivative summary.

Vivani Medical, Inc. director and 10% owner Gregg Williams reported receiving a grant of non-qualified stock options for 36,516 shares of common stock at an exercise price of $1.22 per share. This compensation award was made under the company’s Non-Employee Director Compensation Policy.

The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to Mr. Williams’ continued service through that date, and are scheduled to expire on June 23, 2036.

Vivani Medical, Inc. director Alexandra L. Popoff received an annual non-qualified stock option grant covering 36,516 shares of common stock at an exercise price of $1.22 per share. The option expires on June 23, 2036 and vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to continued service. Following this grant, she holds 36,516 options directly under this award.

Vivani Medical, Inc. director Daniel Bradbury received an annual grant of non-qualified stock options as part of the company’s Non-Employee Director Compensation Policy. The award covers 36,516 options to buy common stock at an exercise price of $1.22 per share, representing 36,516 underlying shares.

The option vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to his continued service as a director. Following this grant, Bradbury holds 36,516 options, and the options are scheduled to expire on June 23, 2036.

Vivani Medical, Inc. director Aaron Mendelsohn received a grant of stock options as part of his non-employee director compensation. He was awarded a non-qualified option covering 36,516 shares of common stock at an exercise price of $1.22 per share, held directly.

The option vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, contingent on continued board service through that date, and expires on June 23, 2036. This is a compensation-related award, not an open-market stock purchase or sale.